Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
As a second objective, the effect of genotype on fear learning will be studied.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of D-cycloserine on Extinction of Fear Conditioning
NCT00352586
Cortisol in the Treatment of Phobias
NCT00451750
D-cycloserine Augmented CBT for Panic Disorder
NCT01680107
D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia
NCT01102803
Effects of Verbal Instructions on Fear Extinction and Extinction Retrieval
NCT05718271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The animal studies are all based on the simple fear learning paradigm of conditioning. However, it is not clear that human anxiety disorders are based on prior conditioning encounter. Therefore it is important to disentangle the effect of DCS on acquisition and extinction in the context of a simple learning paradigm, particular its effect on the human amygdala.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
d-Cycloserine Acquisition
d-Cycloserine will be given on day1, before acquisition
d-Cycloserine
250mg, one dose, 2hrs prior to fMRI
Saliva sample
Buccal cell material will be sampled from all participants on day3
Functional neuroimaging (fMRI)
d-Cycloserine Extinction
d-Cycloserine will be administered on day2, before extinction
d-Cycloserine
250mg, one dose, 2hrs prior to fMRI
Saliva sample
Buccal cell material will be sampled from all participants on day3
Functional neuroimaging (fMRI)
Placebo
A placebo pill will be administered on day1 and 2
Lactose pill
one dose, 2hrs prior to fmri
Saliva sample
Buccal cell material will be sampled from all participants on day3
Functional neuroimaging (fMRI)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
d-Cycloserine
250mg, one dose, 2hrs prior to fMRI
Lactose pill
one dose, 2hrs prior to fmri
Saliva sample
Buccal cell material will be sampled from all participants on day3
Functional neuroimaging (fMRI)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Right-handed
Exclusion Criteria
* The presence of a physical/medical condition that may interfere with the study.
* A contraindication for the use of DCS
* Pacemaker, medication pump (such as insulin pump), hearing aid, removable prosthodontics
* Metal in or on body (such as acupuncture needles, artificial limbs, stents, metal splints, clips, implanted electrodes, tattoos, or piercings)
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catholic University Leuven, Departement of Radiology
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IMDCSACQEXT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.